Novavax starts RSV trial enrollment; Antigenics changes name to Agenus;

Vaccine Research

> Less than a month after MedImmune dropped its marketing application for a drug to prevent respiratory syncytial virus (RSV) disease, Rockville-based Novavax has begun enrolling patients for Phase I trials of its experimental drug to prevent RSV. Story

> Antigenics is changing its name to Agenus. The new name reflects the broadening of the company's product portfolio of clinical candidates beyond autologous antigen-based vaccines, as well as its commitment to actively pursuing licensing opportunities to leverage its development capabilities and expand its product portfolio. Agenus release

> Medicago has announced that a scientific report entitled "Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza," was recently published in the peer-reviewed journal PLoS ONE. Medicago release

> Genocea Biosciences has found some new investors as well as new executives. The Cambridge, MA-based vaccine discovery and development firm has raised $35 million in a Series B funding round, according to a release. The new financing round will help the Harvard spinout to fund development of its lead vaccine for herpes, which is now in preclinical development. Story

Vaccine Market

> A significant rise in the number of whooping cough cases--also called pertussis--has medical experts urging parents to make sure their children's vaccinations are up to date. Article

> More North Dakotans may soon be able to go to their local drugstore to get their flu shots. Senate Bill 2035 would lower the age for those allowed to get shots from pharmacists. Right now, North Dakotans must be 18. News